ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
기관지염 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 7.4%를 나타낼 것으로 예측되고 78억 9,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 호흡기 의학의 발전, 백신 접근성이 확대되다, 맞춤형 소아 치료 접근법, 호흡기 치료 분야의 정밀 의학, 전 세계 흡연 감축 노력 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 맞춤형 치료 접근법, 흡입 요법의 발전, 특정 기관지염 유형에 대한 표적 치료, 예방 및 백신에 주력하는 점, 환자 중심 치료 모델 등이 포함됩니다.
향후 5년간 7.4% 성장이라는 예측은 이전 전망 대비 0.1% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 부과로 스위스 및 인도에서 수입되는 분무기 시스템과 점액 용해제 비용이 증가하여 미국 폐 질환 치료에 차질이 발생할 수 있으며, 이는 호흡기 증상 지속 기간 연장 및 1차 진료 비용 상승으로 이어질 수 있습니다. 또한 상호 보복 관세와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더욱 광범위하게 나타날 것입니다.
호흡기 질환 유병률 증가는 향후 기관지염 치료 시장 성장을 촉진할 것으로 예상됩니다. 호흡기 질환은 폐 및 호흡기 계통의 다른 컴포넌트에 영향을 미치며 상부 또는 하부 호흡기에 영향을 주는 상태를 포함합니다. 감염, 알레르겐, 자극제, 유전적 요인 등 다양한 요인이 이러한 질환에 기여할 수 있습니다. 기관지염 치료는 근본적인 원인과 상태의 중증도에 따라 달라질 수 있으며, 항생제, 항염증제, 기관지 확장제 사용을 통해 기도 확장을 촉진합니다. 예를 들어, 2023년 11월 미국 정부 기관인 노동통계국(Bureau of Labor Statistics)은 2022년 민간 산업 고용주들의 질병 발생률이 2021년 37.7건에서 증가하여 1만 명당 45.2건(FTE 기준)으로 상승했다고 보고했습니다. 이러한 증가는 주로 호흡기 질환 발생률 증가에 기인한 것으로, 2021년 FTE 근로자 1만 명당 27.8건에서 2022년 35.8건으로 급증했습니다. 결과적으로 호흡기 질환 발생률 증가는 향후 기관지염 치료 시장 확장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 기관지염 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 기관지염 치료 시장 : 성장률 분석
세계의 기관지염 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 기관지염 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 기관지염 치료 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 기관지염 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
급성 기관지염
만성 기관지염
세계의 기관지염 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
약물
산소 요법
세계의 기관지염 치료 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
온라인 약국
소매 약국
병원 약국
세계의 기관지염 치료 시장, 급성 기관지염 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항생제
진해재
거담제
기관지 확장제
세계의 기관지염 치료 시장, 만성 기관지염 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
기관지 확장제
코르티코스테로이드
포스포디에스테라아제-4 억제제
증상 악화시 항생제
폐 재활
제7장 지역별 및 국가별 분석
세계의 기관지염 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 기관지염 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
기관지염 치료 시장 : 경쟁 구도
기관지염 치료 시장 : 기업 프로파일
Residential : 개요, 제품 및 서비스, 전략 및 재무 분석
Non-Residential : 개요, 제품 및 서비스, 전략 및 재무 분석
DuPont de Nemours Inc : 개요, 제품 및 서비스, 전략 및 재무 분석
Dorken Coatings GmbH & Co : 개요, 제품 및 서비스, 전략 및 재무 분석
Soprema Group : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
General Aniline & FilmMaterials Corporation
Compagnie de Saint-Gobain SA
Kingspan Group plc
Riwega Srl
Klober ltd.
Knauf Insulation
PIL Membranes Ltd
Dow Chemical Company
Badische Anilin-und Sodafabrik
Carlisle Companies Incorporated
Johns Manville
Sika Group
Firestone Building Products
Covestro AG
Arkema SA
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
기관지염 치료 시장(2029년) : 새로운 기회를 제공하는 국가
기관지염 치료 시장(2029년) : 새로운 기회를 제공하는 부문
기관지염 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Bronchitis treatment involves addressing the inflammation of the bronchial tubes, which results in excessive mucus production. Medications used for this treatment include bronchodilators, steroids, and antibiotics to alleviate symptoms.
The treatment is designed to address both acute and chronic bronchitis, utilizing various approaches such as medications and oxygen therapy. Acute bronchitis is a contagious viral infection leading to inflammation in the bronchial tubes. These treatments are typically available through diverse distribution channels such as online pharmaceutical stores, retail pharmacies, and hospital pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The bronchitis treatment market research report is one of a series of new reports from The Business Research Company that provides bronchitis treatment market statistics, including bronchitis treatment industry global market size, regional shares, competitors with a bronchitis treatment market share, detailed bronchitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bronchitis treatment industry. This bronchitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.61 billion in 2024 to $5.92 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors.
The bronchitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to advancements in respiratory medicine, expanded access to vaccination, tailored pediatric treatment approaches, precision medicine in respiratory care, global efforts to reduce smoking. Major trends in the forecast period include personalized treatment approaches, advancements in inhalation therapies, targeted therapies for specific bronchitis types, focus on prevention and vaccination, patient-centric care models,.
The forecast of 7.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. pulmonary care by increasing costs for nebulizer systems and mucolytic medications imported from Switzerland and India, potentially prolonging respiratory symptoms and raising primary care treatment expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of respiratory diseases is anticipated to drive the growth of the bronchitis treatment market in the future. Respiratory diseases encompass conditions that impact the lungs and other components of the respiratory system, affecting either the upper or lower respiratory tract. Various factors, including infections, allergens, irritants, and genetic factors, can contribute to these diseases. Treatments for bronchitis can vary based on the underlying cause and severity of the condition, involving the use of antibiotics, anti-inflammatories, and bronchodilators to facilitate airway dilation. For example, in November 2023, the Bureau of Labor Statistics, a US government agency, reported that in 2022, the illness rate among private industry employers increased to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This rise was largely attributed to a greater incidence of respiratory illnesses, which escalated from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the growing incidence of respiratory diseases is fueling the expansion of the bronchitis treatment market moving forward.
The growing aging population is poised to contribute to the expansion of the bronchitis treatment market. The aging population phenomenon, characterized by an increasing proportion of elderly individuals within a population, presents a demographic shift with implications for healthcare. Bronchitis treatment in the elderly offers various advantages, addressing both acute and chronic forms of the condition. Benefits include symptom alleviation, complication prevention, improved respiratory function, enhanced ease of breathing, elevated overall quality of life, and reduced hospitalization risks. Globally, the World Health Organization projects that by 2030, 1 in 6 people will be aged 60 or older, with the number doubling to 2.1 billion individuals by 2050. In the UK, the House of Commons Library forecasts a 24% rise in the senior population, reaching 17.4 million people by 2043. The increasing aging population emerges as a significant driver for the growth of the bronchitis treatment market.
Major players in the bronchitis treatment market are focusing on developing technologies like drug-device combination products to improve medication delivery effectiveness and enhance patient adherence to treatment plans. A drug-device combination product integrates a drug with a delivery device to amplify its therapeutic benefits. For example, in July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P. introduced Breyna. This inhalation aerosol is specifically designed for treating asthma and chronic obstructive pulmonary disease (COPD). It comprises a combination of active ingredients, including a long-acting beta-agonist (LABA) and a corticosteroid, which work synergistically to alleviate symptoms and diminish airway inflammation.
Major companies in the Bronchitis Treatment Market are advancing technologies like dry powder inhalers (DPI) to improve drug delivery precision, optimize dosing, and enhance the overall patient experience, making treatment more accessible and user-friendly for individuals with bronchitis. Dry Powder Inhalers (DPI) are devices that administer medication in a dry powder form directly to the lungs, enabling effective treatment of respiratory conditions. For instance, in November 2023, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G. This inhaler combines three active ingredients-vilanterol, fluticasone furoate, and glycopyrronium bromide-into a single device. This innovative formulation aims to provide comprehensive management of COPD symptoms by addressing inflammation, bronchoconstriction, and mucus production simultaneously.
In January 2022, Covis Pharma Group, a Switzerland-based specialty pharmaceutical company, made a strategic move by acquiring the respiratory portfolio of two medicines from AstraZeneca for $270 million. This transaction involved the acquisition of Eklira and Duaklir, positioning Covis to offer a comprehensive range of best-in-class treatments for allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). The acquisition underscores Covis Pharma Group's capability to collaborate effectively and become a preferred partner for major pharmaceutical firms. AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company and a co-developer of a vaccine against bronchiolitis, is the other party involved in this significant transaction. This strategic initiative demonstrates the ongoing efforts of major companies to expand their product portfolios and strengthen their positions in the competitive bronchitis treatment market.
Major companies operating in the bronchitis treatment market include AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories, Sanofi S.A., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Inc., Merck and Co. Inc., Bayer AG, Johnson & Johnson Private Limited, Viatris Inc., Lupin Ltd., Cadila Healthcare Limited, Lincoln Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation, Apotex Inc., Mylan N.V., Eli Lilly and Company, Abbvie, Hetero Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Alkem Laboratories Ltd., Wockhardt Ltd.
North America was the largest region in the bronchitis treatment market in 2024. The regions covered in the bronchitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the bronchitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The bronchitis treatment market includes revenues earned by entities by providing vaccines surgery, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Bronchitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on bronchitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for bronchitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bronchitis treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Acute Bronchitis; Chronic Bronchitis
2) By Treatment: Drugs; Oxygen Therapy
3) By Distribution Channel: Online Pharmaceutical Stores; Retail Pharmacies; Hospital Pharmacies
Subsegments:
1) By Acute Bronchitis: Antibiotics; Antitussives; Expectorants; Bronchodilators
2) By Chronic Bronchitis: Bronchodilators; Corticosteroids; Phosphodiesterase-4 Inhibitors; Antibiotics For Exacerbations; Pulmonary Rehabilitation
Companies Mentioned: AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Dr. Reddy's Laboratories; Sanofi S.A.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Pfizer Inc.; Cipla Inc.; Merck and Co. Inc.; Bayer AG; Johnson & Johnson Private Limited; Viatris Inc.; Lupin Ltd.; Cadila Healthcare Limited; Lincoln Pharmaceuticals Ltd.; Nephron Pharmaceuticals Corporation; Apotex Inc.; Mylan N.V.; Eli Lilly and Company; Abbvie; Hetero Healthcare Ltd.; Torrent Pharmaceuticals Ltd.; Glenmark Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Intas Pharmaceuticals Ltd.; Macleods Pharmaceuticals Ltd.; Alkem Laboratories Ltd.; Wockhardt Ltd.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Bronchitis Treatment Market Characteristics
3. Bronchitis Treatment Market Trends And Strategies
4. Bronchitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Bronchitis Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Bronchitis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Bronchitis Treatment Market Growth Rate Analysis
5.4. Global Bronchitis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Bronchitis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Bronchitis Treatment Total Addressable Market (TAM)
6. Bronchitis Treatment Market Segmentation
6.1. Global Bronchitis Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Bronchitis
Chronic Bronchitis
6.2. Global Bronchitis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drugs
Oxygen Therapy
6.3. Global Bronchitis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Online Pharmaceutical Stores
Retail Pharmacies
Hospital Pharmacies
6.4. Global Bronchitis Treatment Market, Sub-Segmentation Of Acute Bronchitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Antitussives
Expectorants
Bronchodilators
6.5. Global Bronchitis Treatment Market, Sub-Segmentation Of Chronic Bronchitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bronchodilators
Corticosteroids
Phosphodiesterase-4 Inhibitors
Antibiotics For Exacerbations
Pulmonary Rehabilitation
7. Bronchitis Treatment Market Regional And Country Analysis
7.1. Global Bronchitis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Bronchitis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
